


Dietary flavan-3-ol metabolites modulate proinflammatory human fibroblast activation in vitro: potential perspectives in the prevention of CVD

Beatrice Mattina¹, Claudio Curti¹, Pedro Miguel Parreno Mena¹, Claudia Favari¹, Ilaria Zanotti¹, Nicoletta Ronda¹ ¹Department of Food and Drug, University of Parma, Italy

BACKGROUND

Consumption of food rich in flavan-3-ols, like tea, dark chocolate, red wine, grapes, has been associated with a protective effect against chronic diseases characterized by systemic inflammation, such as CVD. Specifically in atherosclerosis, it is known how the deposition and oxidation of LDL particles in the intima of the artery triggers an inflammatory process that becomes chronic and unresolved. This process involves macrophages and fibroblasts, which secrete proinflammatory cytokines such as IL-6 and IL-8 to resolve this damage (Fig.1). Currently, FANS and glucocorticoids are use against the inflammation. These class of drugs are responsible of various side effects. For this reason, there is an increasing research for new molecules characterized by fewer adverse effects.



AIM

This study aims to evaluate the in vitro anti-inflammatory effect of colonic metabolites of flavan-3-ols as OH-PVL, as the most representative molecules present in plasma after the ingestion of flavan-3-ol-containing food.




Fig. 4 The cytotoxicity of all compounds at 1μ M was evaluated in human fibroblast by MTT assay.




Fig. 5 The efficacy of all compounds at $1\mu M$ in inhibiting lipopolysaccharide ($1\mu g/ml$) LPSinduced IL-6 and IL-8 secretion was evaluated in human fibroblast by ELISA kit. Supernatant IL-6 and IL-8 concentrations were normalized against the cell extract protein content, assessed by BCA assay.


% ± s.d.	100 ± 6,90	92 ± 9,62	77 ± 0,61	73 ± 3,03	63 ± 0,91	58 ± 2,05	85 ± 0,08
p-Value	-	ns	0,0158	0,0031	0,0004	0,0091	0,0002

suffering compared to the basal condition. p-value $\leq 0,05$ vs LP condition. The statistical analysis was conducted by one-way ANOVA and post-hoc analysis by Dunnett's test.

	Basal	R-CC01	S-CCO1	R-CC03	S-CC03	R-CC02
IL-6 secretion % ± s.d.	100 ± 13	12 ± 17	16 ± 18	203 ± 288	129 ± 183	63 ± 14
p-Value	ns	ns	ns	ns	ns	ns
IL-8 secretion % ± s.d.	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0
p-Value	ns	ns	ns	ns	ns	ns

Table 2. The IL-6 and IL-8 secretion in basal condition. R-CC01 and S-CC01 showed a reduction in IL-6 secretion vs basal condition B (2833 pg/ml/mg protein) in the absence of inflammatory stimulus. All compounds were found not to stimulate IL-8 secretion vs basal condition (0 pg/ml/mg protein). The statistical analysis was conducted by one-way ANOVA and post-hoc analysis by tukey's test p-value $\leq 0,05$ vs basal condition.

150



CONCLUSIONS

Five OH-PLV compounds have shown anti-inflammatory activity in human fibroblasts in vitro, with no differences between enantiomers. Our data, pointing to the biological activity of specific colonic metabolites of flavan-3-ols, pave the way to further research on the mechanism of action of these molecules and support the usefulness of *in vivo* studies for the prevention and modulation of CVD.

